Goelzer Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $845K | Buy |
1,899
+6
| +0.3% | +$2.67K | 0.05% | 157 |
|
|
2025
Q1 | $918K | Sell |
1,893
-22
| -1% | -$10.7K | 0.05% | 147 |
|
|
2024
Q4 | $771K | Buy |
1,915
+29
| +2% | +$11.7K | 0.04% | 152 |
|
|
2024
Q3 | $877K | Buy |
1,886
+14
| +0.7% | +$6.51K | 0.05% | 145 |
|
|
2024
Q2 | $877K | Sell |
1,872
-12
| -0.6% | -$5.63K | 0.05% | 146 |
|
|
2024
Q1 | $788K | Sell |
1,884
-17
| -0.9% | -$7.11K | 0.04% | 154 |
|
|
2023
Q4 | $773K | Sell |
1,901
-214
| -10% | -$87.1K | 0.05% | 151 |
|
|
2023
Q3 | $735K | Buy |
2,115
+169
| +9% | +$58.8K | 0.05% | 147 |
|
|
2023
Q2 | $685K | Sell |
1,946
-132
| -6% | -$46.5K | 0.06% | 151 |
|
|
2023
Q1 | $655K | Sell |
2,078
-103
| -5% | -$32.5K | 0.06% | 158 |
|
|
2022
Q4 | $630K | Buy |
2,181
+40
| +2% | +$11.6K | 0.05% | 167 |
|
|
2022
Q3 | $620K | Buy |
2,141
+147
| +7% | +$42.6K | 0.06% | 163 |
|
|
2022
Q2 | $562K | Buy |
1,994
+188
| +10% | +$53K | 0.05% | 168 |
|
|
2022
Q1 | $471K | Buy |
1,806
+98
| +6% | +$25.6K | 0.04% | 179 |
|
|
2021
Q4 | $375K | Sell |
1,708
-9,609
| -85% | -$2.11M | 0.03% | 200 |
|
|
2021
Q3 | $2.05M | Buy |
11,317
+6
| +0.1% | +$1.09K | 0.18% | 139 |
|
|
2021
Q2 | $2.28M | Buy |
11,311
+58
| +0.5% | +$11.7K | 0.19% | 139 |
|
|
2021
Q1 | $2.42M | Buy |
11,253
+1,887
| +20% | +$405K | 0.21% | 132 |
|
|
2020
Q4 | $2.21M | Buy |
9,366
+982
| +12% | +$232K | 0.2% | 131 |
|
|
2020
Q3 | $2.28M | Buy |
8,384
+22
| +0.3% | +$5.99K | 0.21% | 122 |
|
|
2020
Q2 | $2.43M | Buy |
8,362
+321
| +4% | +$93.2K | 0.23% | 117 |
|
|
2020
Q1 | $1.91M | Buy |
8,041
+3,037
| +61% | +$723K | 0.22% | 119 |
|
|
2019
Q4 | $1.1M | Buy |
+5,004
| New | +$1.1M | 0.09% | 166 |
|